Cite
HARVARD Citation
Iwama, E. et al. (2020). Survival Analysis for Patients with ALK Rearrangement‐Positive Non‐Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401. Oncologist. pp. 306-e618. [Online].